J Storsaeter
Overview
Explore the profile of J Storsaeter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
821
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zeddeman A, van Gent M, Heuvelman C, van der Heide H, Bart M, Advani A, et al.
Euro Surveill
. 2014 Aug;
19(33).
PMID: 25166348
Pathogen adaptation has been proposed to contribute to the resurgence of pertussis. A striking recent example is the emergence of isolates deficient in the vaccine component pertactin (Prn). This study...
2.
Steens A, Vestrheim D, Aaberge I, Wiklund B, Storsaeter J, Riise Bergsaker M, et al.
Epidemiol Infect
. 2014 Jun;
142(12):2471-82.
PMID: 24932959
For decades, vaccination with the 23-valent polysaccharide pneumococcal vaccine (PPV23) has been available for risk groups aged ⩾2 years to prevent invasive pneumococcal disease (IPD). Recently, a 13-valent pneumococcal conjugated...
3.
Heier M, Gautvik K, Wannag E, Bronder K, Midtlyng E, Kamaleri Y, et al.
Sleep Med
. 2013 Jun;
14(9):867-71.
PMID: 23773727
Background: From October 2009 to January 2010, approximately 470,000 children and adolescents in Norway ages 4-19 years were vaccinated with Pandemrix® against influenza A (H1N1 subtype). The vaccination coverage in...
4.
Hallander H, Paniagua M, Espinoza F, Askelof P, Corrales E, Ringman M, et al.
Vaccine
. 2002 Nov;
21(1-2):138-45.
PMID: 12443672
Serum responses to oral cholera vaccines were assessed in three paediatric vaccine trials, two in León, Nicaragua and one in Stockholm, Sweden. A calibrated anti-cholera toxin B subunit (CTB) IgA...
5.
Olin P, Hallander H, Gustafsson L, Reizenstein E, Storsaeter J
Clin Infect Dis
. 2001 Dec;
33 Suppl 4:S288-91.
PMID: 11709761
Studies on serologic correlates to protection in pertussis were reviewed. Trials in the 1950s showed that agglutinogen titers correlated to protection of whole-cell vaccines, but postvaccination antibodies against pertussis toxin...
6.
Sandbu S, Nokleby H, Helland O, Feiring B, Bondevik M, SUNDELIN F, et al.
Tidsskr Nor Laegeforen
. 2001 Jul;
121(12):1464-8.
PMID: 11449768
Background: A study comparing diphtheria immunity in Norwegian and Russian schoolchildren indicated low immunity against diphtheria in Norwegian children before the booster dose given at age 11 years. The pertussis...
7.
Tiru M, Hallander H, Gustafsson L, Storsaeter J, Olin P
Vaccine
. 2000 Mar;
18(21):2295-306.
PMID: 10717350
Data from two Swedish pertussis vaccine trials with various combination vaccines were used to compare anti-diphtheria antitoxin concentrations over time between different vaccines, vaccine lots and vaccine schedules. The immune...
8.
Blennow M, Gothefors L, Storsaeter J
Lakartidningen
. 1999 Aug;
96(30-31):3320.
PMID: 10459235
No abstract available.
9.
Storsaeter J, Hallander H, Gustafsson L, Olin P
Vaccine
. 1998 Oct;
16(20):1907-16.
PMID: 9796042
Vaccine efficacies against typical pertussis after household exposure to Bordetella pertussis were estimated to be 75.4% for an acellular five-component vaccine, 42.4% for an acellular two-component vaccine, and 28.5%, for...
10.
Ryan M, Murphy G, Ryan E, Nilsson L, Shackley F, Gothefors L, et al.
Immunology
. 1998 Apr;
93(1):1-10.
PMID: 9536112
Recent clinical trials have demonstrated that new generation acellular pertussis vaccines can confer protection against whooping cough. However, the mechanism of protective immunity against Bordetella pertussis infection induced by vaccination...